SEP 2 0 2007 IRSY, 7,801 ATTORNEY 601-1-134PCTUS DOCKET NO. U.S. Department of Commerce Patent and Trademark Office SERIAL NO. 10/521,841 APPLICANT WIEDER, Robert LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT FILING DATE INFORMATION DISCLOSURE STATEMENT July 27, 2005 GROUP 1609 **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT DATE NAME CLASS SUB-**FILING DATE IF** INITIAL **NUMBER** CLASS **APPROPRIATE** FOREIGN PATENT DOCUMENTS **DOCUMENT** DATE COUNTRY **CLASS** SUB-TRANSLATION NUMBER **CLASS** YES NO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) TITLE: AA Korah, et al., Integrin α5β1 Promotes Survival of Growth-Arrested Breast Cancer Cells: An in /M.N./ Vitro Paradigm for Breast Cancer Dormancy in Bone Marrow, Cancer Research, 64: 4514-4522 (2004) /M.N./ AB Stoeltzing et al., Inhibition of Integrin a5β1 Function with a Small Peptide (ATN-161) Plus Continuous 5-Fu Infusion Reduces Colorectal Liver Metastases and Improves Survival in Mice, Int. J. Cancer, 104: 496-503 (2003)

Khalili et al., A Non-RGD-based Integrin Binding Peptide (ATN-161) Blocks Breast Cancer

Braun, et al., Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients, J. Clinical Oncology,

Braun, et al., Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with

Stage I, II or III Breast Cancer, New England Journal of Medicine, 342: 525-534 (2000)

Growth and Metastasis in vivo. Mol. Cancer Ther, 5:2271-2280 (2006)

/M.N./

/M.N./

/M.N./

AC

ΑD

ΑE

18:80-86 (2000)

/M.N./	AF	Wieder, Insurgent Micrometastases: Sleeper Cells and Harboring the Enemy, <i>Journal of Surgical Oncology</i> , 89: 207-210 (2005)
/M.N./	AG	Putz, et al., Phenotypic Characteristics of Cell Lines Derived from Disseminated Cancer Cells in Bone Marrow of Patients with Solid Epithelial Tumors: Establishment of Working Models for Human Micrometastases, <i>Cancer Research</i> , 59:241-248 (1999)
	<u> </u>	
<u> </u>		
EYAMINER:	/Med	era Natarajan/ DATE CONSIDERED: 11/29/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.